Latest Conference Articles

March 15th 2021, 8:58pm

EBMT Meeting

Sergio A. Giralt, MD, discusses the results of a phase 3 trial comparing omidubicel with standard umbilical cord blood transplant in hematologic malignancies.

March 15th 2021, 8:43pm

Omidubicel was associated with a significantly improved median time to neutrophil engraftment compared with standard umbilical cord blood transplantation in patients with high-risk hematologic malignancies.

March 15th 2021, 6:05pm

EBMT Meeting

Brexucabtagene autoleucel displayed significant and durable responses and a reduction in adverse effects in patients with relapsed/refractory mantle cell lymphoma.

March 13th 2021, 1:30pm

PER® New York GU

The emergence of multiple combination regimens with immunotherapy and TKIs has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma; however, without head-to-head comparative data, treatment selection has become individualized based on available patient characteristics.

March 12th 2021, 11:14pm

Treatment options for patients with metastatic urothelial cancer have rapidly expanded as FDA approvals of immunotherapeutics push the boundaries of a once stagnant treatment landscape. Combination regimens and the addition of targeted approaches, further demonstrate progress in areas that have been tough to crack.

March 10th 2021, 9:35pm

HCC-TAG Conference

Anjana Pillai, MD, discusses the importance of multidisciplinary discussion in hepatocellular carcinoma.

March 8th 2021, 7:00pm

PER® Miami Breast Cancer Conference

Olaparib and talazoparib failed to demonstrate statistically significant improvements in overall survival compared with chemotherapy in pretreated patients with BRCA1/2-mutant metastatic HER2-negative breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control

March 7th 2021, 7:12pm

PER® Miami Breast Cancer Conference

One year into the COVID-19 pandemic has allowed for some reflection on the different evolutions that the oncology community went through in response to the many challenges posed by the virus.

March 7th 2021, 3:59pm

PER® Miami Breast Cancer Conference

Stimuli for biologic aging include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction.

March 7th 2021, 3:07pm

PER® Miami Breast Cancer Conference

A wave of approvals and a rapidly evolving treatment landscape could make the next decade a watershed period in breast cancer care.

March 6th 2021, 8:36pm

PER® Miami Breast Cancer Conference

Even in 2021, disparities in outcomes of younger women with breast cancer vs their older counterparts remain; addressing behavioral issues and psychological concerns in this population could vastly improve their quality of life, treatment adherence, and ultimately, survival.

March 6th 2021, 7:30pm

PER® Miami Breast Cancer Conference

Off Our Chests: A Candid Tour Through the World of Cancer is a memoir that dives into Liza Marshall’s breast cancer journey.

March 6th 2021, 7:25pm

PER® Miami Breast Cancer Conference

Although phase 3 data suggest that the addition of checkpoint inhibitors to neoadjuvant chemotherapy could improve pathologic complete response rates for patients with early-stage triple-negative breast cancer, immature data and the risk of long-term toxicity indicate that the therapy is not ready for primetime

March 6th 2021, 7:11pm

PER® Miami Breast Cancer Conference

Kevin Kalinsky, MD, MS, discusses the potential of antibody-drug conjugates across breast cancer subtypes.

March 6th 2021, 6:55pm

PER® Miami Breast Cancer Conference

Hope S. Rugo, MD, discusses the benefit of margetuximab-cmkb in patients with HER2-positive breast cancer who have received prior HER2-targeted therapies.

March 6th 2021, 5:47pm

PER® Miami Breast Cancer Conference

The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.

March 6th 2021, 5:18pm

PER® Miami Breast Cancer Conference

Targeted agents and chemotherapy regimens are at the crux of systemic research efforts focused on improving outcomes for patients with breast cancer who have brain metastases and/or leptomeningeal disease.

March 5th 2021, 10:46pm

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, discusses efforts being made to minimize the risk of disease recurrence in patients with early-stage HER2-positive breast cancer.

March 5th 2021, 10:37pm

PER® Miami Breast Cancer Conference

Olufunmilayo Falusi Olopade, MD, FACP, discusses racial disparities in breast cancer outcomes.

March 5th 2021, 9:30pm

PER® Miami Breast Cancer Conference

With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients with breast cancer, it’s become understood that genetic profiling can define clinical trial eligibility, the presence or absence of aberrations help to drive treatment decisions, and variants can be predictive for response or resistance.